Ann: Radiopharm targets Nasdaq Listing by end of 2024, page-5

Second attempt, first in early 2023 was abondened.

Going by the new register RAD is a US pharma / investor held company and will be shifted to the US when Lantheus thinks it makes sense. Lantheus is calling the shots and providing future fundings. ASX wasn't interested, Hopper's only option was to sell it to Lantheus by leaving us retail some hope of picking up the crumbs.

In the end the best outcome for sh, avoiding a possible total loss and if buying now truckloads at sub "take over" price those IPO 60c buyers might even get their losses back should we get forced to hand over our shares at 5-10c.

Similar scenario looming for CHM with an anns imminent as the next placement must be done and dusted by mid September.

Not sure why someone had to dump but maybe the word NASDAQ-Listing now means failure.

Money talks and that has been secured at this stage for a long time. The Ts&Cs favour Hopper and the big guys but has that ever been any different?

GLTA